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The humanized monoclonal antibody ATROSAB is tar-
geting specifically the TNF receptor 1(TNFR1). TNF is a
central mediator of inflammation and key target for
intervention in inflammatory diseases such as rheuma-
toid arthritis, psoriasis and Crohn’s Diseases. Notably,
blockade of the second TNF receptor, TNFR2, has been
associated with increased sensitivity to viral infections or
increased susceptibility to demyelinating disorders and
lymphomas. In this context, a selective inhibition of
TNF-induced TNFR1 but not TNFR2 signaling activity
holds great promises to overcome undesired effects
observed with less specific TNF antagonists currently
used in clinic.
The recently humanized antibody was used to estab-
lish a rCHO-K1 cell line under serum-free, chemically
defined conditions (1). The process development was
based on two sets of shake flask experiments, three 10L
bioreactor runs and finally 2 GMP production runs in
300 L scale. The scale up strategy was based on quality
by design considerations specified in the design space
for the scale-up parameters. The main parameter for the
scale-up development was mixing time as a function of
the bioreactor geometry, tip-speed, Reynolds number,
and the power input of the systems. Those parameters
are generally considered as important parameters during
up-stream process development.
Protein characteristics were specified based on several
considerations. A major part was the ICH-Q8 guideline
as well as antibody and other drug guidelines. The other
part is based on experience with antibody development
and the specific protein in special. The specifications are
described in Table 1. The analytical methods used to
characterize the antibody were SDS-PAGE, western blot,
HPLC-SEC, protein A HPLC, HPAEC-PAD, Isoelectric
focusing and a cell based potency assay. As the antibody
is declined to bind to the TNF-R1 on target cells, it was
engineered not to elicit ADCC or CDC. Therefore those
parameters were not checked during process
development.
The basal medium was fixed to a commercial available
chemically defined medium during clone screening. In a
batch process, performed in a fully equipped 1L bioreac-
tor, a titer of approximately 180 mg/L was obtained. At
this stage the antibody was characterized and specifica-
tions were partly narrowed and some were newly set. In
the first step of process development different feeding
solutions and concentrations thereof were tested in
shake flask experiments. Metabolite data were moni-
tored on a daily basis comprising glucose, lactate,
ammonia, and amino acid levels. Additionally cell den-
sity and protein concentration were measured at the
same time interval. For in-depth protein characteriza-
tion, supernatant was purified after 6 days of fermenta-
tion and at harvest, in order to check the quality
attributes already early at the development stage. This
step led to an increase of about 2.5 fold in product con-
centration, while the protein characteristics stayed
within specifications at both sampling time points. The
second step was the optimization of the feeding strategy
as well as the fortification of the solutions with certain
chemically defined supplements. This led to another
increase of about 2.5 fold regarding final product con-
centration. Product quality changed slightly, but stayed
within specifications. Especially the glycosylation struc-
ture changed towards less glycosylated versions.
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The process was finally scaled up to the 300L stirred
tank bioreactor in the GMP facility. An engineering run
was performed to test the process and product para-
meters. Some influence was measured, thus the process
was slightly changed prior the first GMP run. The
obtained product quality was well within specifications,
the achieved titer was more than 1.2 g/L, which was a
more than 7 fold increase in comparison to the initial
batch process. Although the cell density profile of the
process changed between run 1 and 2, the volumetric
product concentration was only slightly below 1.2 g/L
and the product characteristics were identical to the
first run. This indicates the robustness of the developed
p r o c e s sa n dt h ev a l i d i t yt od e f i n ea n ds p e c i f yd e s i g n
spaces for process development especially during scale-
up development. The analysis of protein characteristics
employing SDS-PAGE, IEF, HP-SEC, potency assay and
glycosylation pattern with HPAEC-PAD ensures the
quality of the protein.
Table 1 specified scale-up parameters and defined protein characteristics
scale-up parameter protein characteristics
Parameter Design Space 300L GMP specifications defined at the
project start
300L GMP
Mixing Time [s] 10 - 70 max. 60 Isoforms (IEF) pH 7.6 - 8.8
Tip-Speed [m/s] 0.6 - 1.2 max. 1.0 Glycosylation
(HPAEC-PAD)
Mol% of different forms ± 20% from clone
screening
Reynolds
Number
1 - 8 Mio max. 6 Mio Potency 40% - 160% from clone screening
Power Input [W/
m3]
25 - 1100 max. 650 Molecular weight
(SDS-PAGE)
Main Band at app. 150 kDa
Gassing Head Space / Ring
Sparger
Head Space & Ring
Sparger
Immunogenic glycostructures none
Agitation orbital sh., Rushton I. Rushton I. Purity (HP-SEC) > 90%
Figure 1 The left diagram shows the cell density of two GMP runs in the 300L bioreactor. The right diagram focuses on the achieved product
concentrations during the different process development steps. The batch experiment was performed in 1L bioreactors, the feed screening was
done in 250 mL shake flasks. The feed optimization was performed in 10L bioreactors and the GMP runs were done in a 300L stirred tank
bioreactor in a GMP facility.
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